Summit Therapeutics financials
$16.39+5.88%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Jan 31 | FY16 Jan 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $705.0K | $1.8M | $860.0K | $57.1M | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $705.0K | $1.8M | $860.0K | $57.1M | — |
| Gross margin | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$1.09B | -$226.0M | -$609.6M | -$72.1M | -$86.2M | -$53.2M | $5.4M | -$29.7M |
| Net income | -$1.08B | -$221.3M | -$614.9M | -$78.8M | -$88.6M | -$52.7M | $10.9M | -$29.4M |
| Net margin | — | — | — | −11174.8% | −4897.8% | −6127.6% | 19.0% | — |
| Diluted EPS | $-1.44 | $-0.31 | $-0.99 | $-0.41 | $-0.67 | $-0.76 | $0.63 | $-0.50 |
| EBITDA | -$1.09B | -$225.9M | -$609.5M | -$62.4M | -$83.7M | -$50.3M | $12.6M | -$29.6M |
| Operating cash flow | -$322.9M | -$142.1M | -$76.8M | -$41.6M | -$72.6M | -$48.1M | -$35.1M | — |
| Free cash flow | -$323.6M | -$142.2M | -$76.9M | -$42.2M | -$72.9M | -$48.5M | -$35.3M | — |
| Diluted shares | 747.7M | 718.5M | 619.6M | 193.3M | 131.7M | 69.5M | 17.2M | 59.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $225.3M | $104.9M | $71.4M | $348.6M | $71.8M | $66.4M |
| Short-term investments | $488.2M | $307.5M | $114.8M | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $100.0M | $514.3M | $0.00 | $0.00 |
| Total assets | $751.2M | $435.6M | $202.9M | $664.2M | $113.4M | $102.5M |
| Total liabilities | $92.3M | $46.8M | $125.3M | $537.5M | $30.1M | $23.0M |
| Shareholders' equity | $658.9M | $388.7M | $77.7M | $126.7M | $83.3M | $79.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology